Zymeworks clocks up milestones with lead asset and platform

30 May 2019

The share price of Canadian biopharma Zymeworks (TSX: ZYME) closed up 4% on Wednesday after the company received two separate validations of its approach.

One of the announcements concerned the company’s lead asset ZW25, which was granted Fast Track designation by the US Food and Drug Administration (FDA).

ZW25 is a new Azymetric bispecific antibody being studied in a Phase II trial treating patients with HER2-overexpressing gastroesophageal adenocarcinoma in combination with standard-of-care chemotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK